GlassScriptPhysician profile
Shawn K Hall
NPI 1306844147
$5,495.14
in general payments reported to CMS, 2019-2025
42 companies · $967 in 2025
The $967 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $696 · 2020: $448 · 2021: $732 · 2022: $1,034 · 2023: $753 · 2024: $864 · 2025: $967.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,585.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,584.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,094.08 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $998.20 | 2020-2025 | |
| Astellas Pharma US INC | $515.18 | 2019-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $438.91 | 2019-2025 | |
| Novo Nordisk INC | $313.62 | 2019-2025 | Wegovy, Saxenda |
| Amgen INC. | $278.73 | 2019-2025 | Otezla, Repatha, Otezla |
| Abbott Laboratories | $212.30 | 2022-2025 | Freestyle Libre 3, Perclose Proglide |
| Janssen Pharmaceuticals, INC | $134.43 | 2019-2022 | |
| Lilly USA, LLC | $121.61 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Jazz Pharmaceuticals INC. | $105.83 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $104.79 | 2021-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $76.97 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $76.61 | 2021-2022 | |
| Axsome Therapeutics, INC. | $73.62 | 2025 | Auvelity |
| Astrazeneca Pharmaceuticals LP | $66.58 | 2019-2020 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shawn Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.